ResourcesVendorsRadiopharmaceuticalsRadiopharmeceuticals Nuclear MedicineImaginAb, Inc.423 HINDRY AVE SUITE DeMail:Website:https://www.imaginab.comLatest from ImaginAb, Inc.Nuclear MedicineImaginAB licenses immuno-PET tracer to LeucidBy AuntMinnie.com staff writersImmuno-PET developer ImaginAB has licensed its zirconium-89 crefmirlimab berdoxam radiotracer to biotech company Leucid for use in studies of solid tumors.April 11, 2023CTFirst patient dosed with CD8 ImmunoPET in ImaginAb clinical trialBy AuntMinnie.com staff writersThe first patient has been dosed in a clinical trial assessing immuno-PET developer ImaginAb's PET/CT imaging agent CD8 ImmunoPET.October 24, 2022Molecular ImagingImaging Endpoints, ImaginAb expand partnershipBy AuntMinnie.com staff writersContract research organization Imaging Endpoints and immuno-PET developer ImaginAb have inked a license agreement to supply clinical doses of ImaginAb's investigational zirconium-89 crefmirlimab berdoxam CD8 Immuno-PET agent to biopharma companies.June 6, 2022Nuclear MedicineImaginAb inks deal with pharma developer in ChinaBy AuntMinnie.com staff writersImmuno-PET developer ImaginAb has signed an exclusive license with DongCheng Pharmaceutical Group to commercialize cancer imaging radiotracers across China.May 24, 2022Molecular ImagingImaginAb sets sight on Chinese marketBy AuntMinnie.com staff writersImmuno-PET developer ImaginAb has inked a partnership with DongCheng Pharmaceutical Group with the goal of achieving market authorization in China for cancer imaging radiotracers.January 26, 2022Nuclear MedicineImaginAb signs new agreement with Boehringer IngelheimBy AuntMinnie.com staff writersImaginAb has signed a new license agreement to supply its ImmunoPET radiotracer to Boehringer Ingelheim.July 22, 2021Molecular ImagingAbcuro, ImaginAb tout Immuno-PET study resultsBy AuntMinnie.com staff writersAbcuro and ImaginAb are highlighting the results of a study using the Immuno-PET radiotracer to show that CD8+ T-cells are present throughout the skeletal muscle system in patients with inclusion body myositis.June 29, 2021Nuclear MedicineImaginAb lands $13M in growth fundingBy AuntMinnie.com staff writersRadiopharmaceutical developer ImaginAb has raised almost $13 million in funding to support the company's growth and further development of its CD8 Immuno-PET agent.June 2, 2021Molecular ImagingAuntMinnie.com Molecular Imaging InsiderBy Brian CaseyJanuary 12, 2021Molecular ImagingImaginAb, Pfizer ink deal on PET agentBy AuntMinnie.com staff writersImaging agent developer ImaginAb signed a multiyear, nonexclusive license with Pfizer to supply the zirconium-89 CD8 Immuno-PET agent, which can be used to image CD8 T cells in cancer patients.January 7, 2021Molecular ImagingClarity, ImaginAb team to develop theranostic agentsBy AuntMinnie.com staff writersRadiopharmaceutical firm Clarity Pharmaceuticals and imaging agent developer ImaginAb are collaborating to develop new targeted theranostic products for a range of cancer types.July 20, 2020Nuclear MedicineBWXT appoints new president for BWXT ITG CanadaBy AuntMinnie.com staff writersU.S. government nuclear components supplier BWX Technologies (BWXT) has hired nuclear medicine industry veteran Martyn Coombs to be president of its BWXT ITG Canada medical radioisotope division, effective July 20.July 6, 2020Molecular ImagingImaginAb inks partnership with ARTMSBy AuntMinnie.com staff writersImaging agent developer ImaginAb has formed a strategic partnership with Canadian radioisotope production technology developer ARTMS Products.April 7, 2020Molecular ImagingImaginAb inks licensing deal with AstraZenecaBy AuntMinnie.com staff writersImaging agent developer ImaginAb has signed a multiyear license agreement with AstraZeneca.March 29, 2020Molecular ImagingImaginAb signs collaboration deal with 3 firmsBy AuntMinnie.com staff writersImaging agent developer ImaginAb has signed a collaboration agreement with pharmaceutical companies AstraZeneca, Pfizer, and Takeda Pharmaceutical to further the clinical development of its CD8 PET technology.October 14, 2019
